The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

CONCLUSION: IDC-P on biopsy pathology was found to be an independent risk factor to predict a poor pathology response of primary CaP to neoadjuvant therapies.PMID:38233262 | DOI:10.1016/j.urolonc.2023.11.018

Source: Urologic Oncology - January 17, 2024 Category: Urology & Nephrology Authors: Binyu Wang Yao Fu Mengxia Chen Shan Peng Giancarlo Marra Junlong Zhuang Shiwei Zhang Hongqian Guo Xuefeng Qiu Source Type: research